Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Whitney Hunter

Physician Assistant, Medical Pensacola, FL Physician Assistant

NPI 1508146796 CMS profile 10419572

545 Brent Lane, Pensacola, FL 32503

Open in the dashboard

General payments

$10,402

343 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Whitney Hunter of Pensacola, FL is reported in the CMS Open Payments database as having received $10,402 across 343 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,681 60
2024 General $2,241 85
2023 General $2,643 85
2022 General $3,357 99
2021 General $480 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Whitney Hunter
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Whitney Hunter were reported at $1,681. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Whitney Hunter Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $480 $156 $41–$563 $132
2022 $3,357 $185 $55–$649 $149
2023 $2,643 $199 $58–$717 $160
2024 $2,241 $206 $62–$740 $164
2025 $1,681 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Axonics Modulation Technologies, Inc. $1,923 16 payments
  2. Medtronic, Inc. $1,479 30 payments
  3. Coloplast Corp $1,103 27 payments
  4. Janssen Biotech, Inc. $842 35 payments
  5. AbbVie, Inc. $669 56 payments
  6. Myriad Genetic Laboratories, Inc. $519 17 payments
  7. Antares Pharma, Inc. $362 23 payments
  8. Sumitomo Pharma America, Inc. $357 20 payments
  9. Dendreon Pharmaceuticals LLC $309 7 payments
  10. Merck Sharp & Dohme Corporation $274 13 payments
  11. Other $2,565 99 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,176 335 payments
  2. Travel and Lodging $1,226 8 payments
Products named General payments · program years 2021–2025
  1. Axonics $1,911 15 payments
  2. INTERSTIM $1,461 29 payments
  3. SpeediCath $931 25 payments
  4. ERLEADA $695 34 payments
  5. XYOSTED $404 26 payments
  6. ORGOVYX $332 16 payments
  7. BOTOX Botox Therapeutic $325 32 payments
  8. PROVENGE $309 7 payments
  9. XIAFLEX $295 14 payments
  10. BOTOX Urology $290 20 payments
  11. Other $5,010 200 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

825

Median for Physician Assistant: 241

Drug cost

$817,782

Median for Physician Assistant: $4,110

Branded share of claims

41.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erleada Apalutamide Brand 22 $330,358
Xtandi Enzalutamide Brand 20 $284,792
Abiraterone Acetate Generic 39 $76,449
Gemtesa Vibegron Brand 83 $57,952
Orgovyx Relugolix Brand 12 $31,058
Myrbetriq Mirabegron Brand 26 $18,645
Methenamine Hippurate Generic 65 $8,265
Alfuzosin Hcl Er Alfuzosin Hcl Brand 104 $2,281
Tamsulosin Hcl Generic 140 $1,763
Potassium Citrate Er Potassium Citrate Brand 21 $1,392

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$64,989

Of which drugs: $38,669

Medicare patients

232

Average age 72

Services billed

6,225

78 women, 154 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 40%
Cancer 38%
Diabetes 33%
Chronic kidney disease 33%
Depression 25%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $151
$151 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $129
$129 83 —
Trodelvy
  • Gilead Sciences, Inc. $125
$125 — —
ERLEADA
  • Janssen Biotech, Inc. $118
$118 22 —
AKEEGA
  • Janssen Biotech, Inc. $118
$118 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

343 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record